News
MapLight Therapeutics initiates phase 2 ZEPHYR study of M1/M4 muscarinic agonist ML-007C-MA to treat schizophrenia: Redwood City Thursday, July 10, 2025, 13:30 Hrs [IST] MapLight ...
Lone Tree, Colorado Thursday, July 10, 2025, 13:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback